The market is flooded with ‘n‘ number of mediclaim policies, which confuse the investors. In an interview to CNBC-TV18, Harshvardhan Roongta, gives us more clarity on which mediclaim is best suited.
first published: Nov 22, 2012 01:02 pm
A collection of the most-viewed Moneycontrol videos.

Rupee Slide Weighs Heavy As Nifty Tests 25,900| Midcaps See Sharp Cuts| Closing Bell Live

Meesho's Rs 5,421 Cr IPO Kicks Off| Post-IPO Playbook, Profitability Path & More| IPO Watch Live

Can Nifty Hold Above 26,000 Amid Currency Jitters? Meesho IPO Opens | Opening Bell Live

Nifty Struggles Below 26,100 On Weekly F&O Expiry As Rupee Hits New Low| Closing Bell Live
You are already a Moneycontrol Pro user.

